Stelara

Drug Overview
Product Profiles
Stelara: Crohn's disease
Stelara: Psoriatic arthritis
Stelara: Ulcerative colitis
Stelara: Psoriasis

Figure 5: Filgotinib for Crohn’s disease – SWOT analysis
Figure 4: Filgotinib for Crohn’s disease – SWOT analysis
Figure 21: The authors drug assessment summary of Stelara in Crohn’s disease
Figure 11: The authors drug assessment summary of Cimzia in Crohn’s disease
Figure 25: The authors drug assessment summary of Tysabri in Crohn’s disease
Figure 6: Ozanimod sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 28: The authors drug assessment summary of ozanimod in Crohn’s disease
Figure 15: Upadacitinib for Crohn’s disease – SWOT analysis

Table 1: Stelara drug profile
Table 2: Stelara sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 3: Stelara drug profile
Table 4: Stelara pivotal trial data in psoriatic arthritis
Table 5: Stelara drug profile
Table 6: Stelara drug profile
Table 7: Stelara pivotal trial data in adult psoriasis
Table 8: Stelara pivotal trial data in adolescent psoriasis
Table 9: Stelara late-phase trial data in psoriasis
Table 10: Cumulative rates of adjudicated major adverse cardiovascular events in five-year follow-up study on Stelara
patients
Table 11: Treatment-emergent infections in patients treated with Stelara through up to five-year follow-up